Cash/Burn From SEC Filing For Period: 

Q3 '19

VNDA

Vanda Pharmaceuticals

Vanda is developing important new medicines to improve the lives of patients. We use new technologies, including genetics and genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds.

Cash

$237.8M

Burn Rate

-

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Tasimelteon (Hetlioz)

Jet Lag Disorder

Approved

Tradipitant

Atopic dermatitis Pruritus

Phase 3 Ongoing

Tradipitant

Motion Sickness

Phase 3

Iloperidone (Fanapt)

Long Acting Injectable

Phase 3

Iloperidone (Fanapt)

Bipolar Disorder

Phase 3

Tasimelteon (Hetlioz)

Smith-Magenis Syndrome

Phase 3

Tasimelteon (Hetlioz)

Delayed Sleep Phase Disorder

Phase 3

Tradipitant

Gastroparesis

Phase 3

Tasimelteon (Hetlioz)

Non-24 Pediatric

Phase 3

VTR-297

Hematologic Malignancies

Phase 1

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon